BLCO
$17.05
+$0.07 (0.41%)+0.41%
ClosedLoading chart...
IndexN/A
Market Cap6.09B
Enterprise Value11.03B
Income$-0.21B
Sales$1.14B
EmployeesN/A
P/E26.23
P/S1.18
P/B0.94
P/C-91.56
EV/EBITDA20.62
EV/SalesN/A
EPS (ttm)0.65
EarningsN/A
Gross Margin54.75%
Oper. Margin3.69%
Profit Margin-7.06%
Volume0.19M
Shs Outstand0.36B
Change0.41%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | $4.79B | $4.15B | $3.77B | $3.77B | $3.41B | $3.78B | $3.67B |
| Cost of Revenue | $1.87B | $1.64B | $1.52B | $1.47B | $1.28B | $1.33B | $1.31B |
| Gross Profit | $2.92B | $2.50B | $2.25B | $2.30B | $2.13B | $2.45B | $2.35B |
| Gross Margin | 60.93% | 60.40% | 59.69% | 61.04% | 62.34% | 64.88% | 64.17% |
| Operating Expenses | $2.76B | $2.37B | $2.04B | $1.97B | $1.87B | $2.06B | $1.94B |
| Operating Income | $162.00M | $130.00M | $207.00M | $329.00M | $260.00M | $396.00M | $416.00M |
| Operating Margin | 3.38% | 3.14% | 5.49% | 8.74% | 7.62% | 10.48% | 11.35% |
| Net Income | $-317.00M | $-260.00M | $6.00M | $182.00M | $-18.00M | $298.00M | $710.00M |
| Net Margin | -6.62% | -6.27% | 0.16% | 4.83% | -0.53% | 7.89% | 19.37% |
| EPS (Basic) | $-0.90 | $-0.74 | $0.04 | $0.52 | $-0.05 | $0.85 | $2.03 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $13.47B | $13.44B | $11.14B | $10.82B | $11.27B | $11.47B | $0.00 |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $6.92B | $6.52B | $4.04B | $1.42B | $1.28B | $1.44B | $0.00 |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $6.47B | $6.85B | $7.03B | $9.33B | $9.92B | $9.96B | $0.00 |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $6.47B | $6.85B | $7.03B | $9.33B | $9.92B | $9.96B | $0.00 |
| Total Liabilities & Stockholders Equity | $13.47B | $13.44B | $11.14B | $10.82B | $11.27B | $11.47B | $0.00 |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Net Income | $-317.00M | $-260.00M | $6.00M | $182.00M | $-18.00M | $298.00M | $710.00M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $232.00M | $-17.00M | $345.00M | $873.00M | $522.00M | $799.00M | $763.00M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Ophthalmology Devices Market Report Released, Includes Profiles of EssilorLuxottica, Alcon, Bausch + Lomb, and 20 OthersGlobeNewswire Inc. A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the StoryThe Motley Fool Bausch + Lomb Corporation Investigated by the Portnoy Law FirmGlobeNewswire Inc. Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major PositionThe Motley Fool Global Ophthalmic Drugs Market Estimated at US$41.88 Billion in 2026; Projected to Grow at 7.9% CAGR Through 2036GlobeNewswire Inc. Nicox présente des données de Phase 3 positives confirmant le profil thérapeutique de NCX 470 lors du congrès annuel 2026 de l’American Glaucoma Society (AGS)GlobeNewswire Inc. Nicox : Présentation des données des études de Phase 3 de NCX 470 au congrès annuel 2026 de l’American Glaucoma Society (AGS)GlobeNewswire Inc. Nicox annonce sa participation à des congrès au premier semestre 2026 et la présentation prochaine de données scientifiquesGlobeNewswire Inc.
Show 12 more stories
Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data PresentationsGlobeNewswire Inc. Contact Lens Market Size to Hit USD 26.64 Billion by 2033, Driven by Rising Vision Care Awareness and Technological Advancements – SNS InsiderGlobeNewswire Inc. LASIK Eye Surgery Market Size to Reach USD 3.77 Billion by 2033, Driven by Rising Vision Correction Demand – SNS InsiderGlobeNewswire Inc. Intraocular Lens Market Size to Reach USD 9.85 Billion by 2033, Growing at a CAGR of 6.48% - SNS InsiderGlobeNewswire Inc. Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past YearThe Motley Fool BLCO Stock Still 16% Below IPO — Is Silver Point’s $38.7 Million Bet a Turning Point?The Motley Fool Activist Investor Drops Scathing Letter, Slams Cooper's 'Growth At All Costs' ApproachBenzinga New Eye Tech Is Booming For Alcon, Stock SoarsBenzinga Activist Investor Seeks Strategic Overhaul At Contact Lens Maker Cooper, Suggests Merger With Bausch + LombBenzinga Contact Lenses Market Trends, Shares, Strategies and Growth Analysis Report (2025-2034) Featuring Alcon Vision, Bausch & Lomb, J&J Vision Care, CooperVision, Essilor International and MoreGlobeNewswire Inc. Global Myopia Treatment Devices Market Poised for Strong Growth at a CAGR of ~8% by 2032, Driven by Technological Innovations and Increasing Eye Care Demand | DelveInsightGlobeNewswire Inc. Nicox prévoit de rembourser intégralement ses dettes financières, NCX 470 ayant été dé-risqué et licencié dans le monde entierGlobeNewswire Inc.
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
Discover more
You may be interested in